TrialJournal of Crohn's & colitis2018

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

William J Sandborn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.